Extracellular matrix of ovarian tumors.

Tumor cells interfere with the normal programming of extracellular matrix (ECM) biosynthesis and can extensively modify the structure and composition of the matrix. The role of ECM components is becoming increasingly recognized as an important determinant for the growth and progression of solid tumors. The extensive remodeling of the normal ECM in tumors can proceed through the degradation of pre-existing ECM molecules and/or by the neosynthesis of ECM components, which in many cases are not present in the ECM of normal tissues. In the ovary the ECM comprises a variety of molecules including the collagen superfamily and noncollagenous proteins such as glycoproteins, proteoglycans, and hyaluronan. Elevated levels of laminin-gamma2, collagen types I and III, fibronectin, syndecan-1, glypican-1, versican, and hyaluronan and its receptors CD44 have all been associated with a poor prognosis of ovarian cancers. Generally, there is a differential expression of laminin chains alpha1, alpha4, and beta2 among serous (alpha1, beta2), mucinous (alpha4), and endometrioid (alpha1) tumors. This review focuses on these and other ECM molecules in ovarian tumors.

[1]  G. Rosen,et al.  Expression of Fibronectin and Its Cell Surface Receptors , 1991 .

[2]  B. Toole,et al.  Expression of Hyaluronan in human tumor progression , 2006, Journal of carcinogenesis.

[3]  A. Skubitz,et al.  Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells , 2004, Clinical & Experimental Metastasis.

[4]  F. Hirahara,et al.  Wide Distribution of Laminin-5 γ2 Chain in Basement Membranes of Various Human Tissues , 1998, Hormone Research in Paediatrics.

[5]  Anthony J. Guidi,et al.  Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  C. Haglund,et al.  Epithelial and stromal syndecan‐1 expression as predictor of outcome in patients with gastric cancer , 2001, International journal of cancer.

[7]  D. Horsfall,et al.  Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  C. Sheehan,et al.  Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. , 2001, American journal of clinical pathology.

[9]  V. Kosma,et al.  CD44 expression indicates favorable prognosis in epithelial ovarian cancer. , 2003, Clinical Cancer Research.

[10]  A. Loercher,et al.  In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. , 1999, Cancer research.

[11]  V. Kosma,et al.  High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. , 2000, Cancer research.

[12]  V. Kosma,et al.  Versican in epithelial ovarian cancer: Relation to hyaluronan, clinicopathologic factors and prognosis , 2003, International journal of cancer.

[13]  H. Dvorak,et al.  Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. , 1996, The American journal of pathology.

[14]  H. Tamaki,et al.  Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  L. Hawthorn,et al.  Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. , 2005, Oncology reports.

[16]  R. Ádány,et al.  Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. , 1990, The Journal of biological chemistry.

[17]  P. Marynen,et al.  Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. , 1997, Genomics.

[18]  P. Heitz,et al.  Distribution of the large aggregating proteoglycan versican in adult human tissues. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[19]  L. Heickendorff,et al.  Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. , 2001, Clinical chemistry.

[20]  R. Einspanier,et al.  Hyaluronan in the bovine oviduct—modulation of synthases and receptors during the estrous cycle , 2004, Molecular and Cellular Endocrinology.

[21]  D. Katsaros,et al.  Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells , 2002, Oncogene.

[22]  A. Skubitz,et al.  CD44 and β1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins , 2004, Clinical & Experimental Metastasis.

[23]  L. Rodriguez-Rodriguez,et al.  The CD44 receptor is a molecular predictor of survival in ovarian cancer , 2003, Medical oncology.

[24]  A. Godwin,et al.  Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity , 2002, Cancer.

[25]  J. McDonald,et al.  Characterization and Molecular Evolution of a Vertebrate Hyaluronan Synthase Gene Family* , 1998, The Journal of Biological Chemistry.

[26]  J. Risteli,et al.  Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. , 1996, The American journal of pathology.

[27]  J. Rabczyński,et al.  Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. , 2004, Gynecologic oncology.

[28]  P. Mullen,et al.  Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines , 1999, British Journal of Cancer.

[29]  M. Hung,et al.  Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and Growth* , 2001, The Journal of Biological Chemistry.

[30]  K. Sobolewski,et al.  Accumulation of collagen in ovarian benign tumours. , 1999, Acta biochimica Polonica.

[31]  O. Dapunt,et al.  Prognostic value of CD44 splice variant expression in ovarian cancer. , 1995, Oncology.

[32]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[33]  J. Weinberg,et al.  Increased levels of laminin in ascitic fluid of patients with ovarian cancer. , 1995, Cancer letters.

[34]  L. Zardi,et al.  Fibronectin as target for tumor therapy , 2006, International journal of cancer.

[35]  U. Schumacher,et al.  Expression of hyaluronate and hyaluronate synthase in human primary tumours and their metastases in scid mice. , 2002, Cancer letters.

[36]  V. Kosma,et al.  Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. , 2002, Cancer research.

[37]  J. Niloff,et al.  CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Labat-Robert,et al.  Fibronectin in malignancy. , 2002, Seminars in cancer biology.

[39]  H. Heinzl,et al.  Prognostic value of laminin-5 in serous adenocarcinomas of the ovary. , 2002, Anticancer Research.

[40]  U. Puistola,et al.  Aminoterminal propeptide of type III procollagen in ovarian cancer , 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.

[41]  I. Weber,et al.  Model Structure of Decorin and Implications for Collagen Fibrillogenesis* , 1996, The Journal of Biological Chemistry.

[42]  H. Rochefort,et al.  Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Langdon,et al.  Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. , 1996, British Journal of Cancer.

[44]  É. Álvarez,et al.  Splice variant expression of CD44 in patients with breast and ovarian cancer. , 2001, Oncology reports.

[45]  M. Weber,et al.  Basement membrane proteins. , 1992, Kidney international.

[46]  V. Hascall,et al.  Localization and synthesis of hyaluronic acid in the cumulus cells and mural granulosa cells of the preovulatory follicle. , 1992, Developmental biology.

[47]  A. J. Day,et al.  Hyaluronan-binding Proteins: Tying Up the Giant* , 2002, The Journal of Biological Chemistry.

[48]  E. Lillehoj,et al.  Normal and abnormal aspects of proteinuria. Part I: Mechanisms, characteristics and analyses of urinary protein. Part II: Clinical considerations. , 1986, Experimental pathology.

[49]  J. Sanes,et al.  A simplified laminin nomenclature. , 2005, Matrix biology : journal of the International Society for Matrix Biology.

[50]  T. Wight,et al.  Versican: a versatile extracellular matrix proteoglycan in cell biology. , 2002, Current opinion in cell biology.

[51]  P. Prehm.  Release of hyaluronate from eukaryotic cells. , 1990, The Biochemical journal.

[52]  Scully Re,et al.  World Health Organization classification and nomenclature of ovarian cancer. , 1975, National Cancer Institute monograph.

[53]  R. Rodgers,et al.  Characterization of the expression of the alternative splicing of the ED-A, ED-B and V regions of fibronectin mRNA in bovine ovarian follicles and corpora lutea. , 1999, Reproduction, Fertility and Development.

[54]  P. Speiser,et al.  CD-44 is not involved in the metastatic spread of ovarian cancer in vivo. , 1995, Anticancer research.

[55]  David I. Smith,et al.  Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. , 2002, Cancer research.

[56]  M. Tammi,et al.  Hyaluronan and Homeostasis: A Balancing Act* , 2002, The Journal of Biological Chemistry.

[57]  V. Hascall,et al.  Coding sequence of a hyaluronan synthase homologue expressed during expansion of the mouse cumulus-oocyte complex. , 1997, Archives of biochemistry and biophysics.

[58]  E. Hay,et al.  Cell Biology of Extracellular Matrix , 1988, Springer US.

[59]  M. Barbareschi,et al.  High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis , 2003, Cancer.

[60]  M. L. Harland,et al.  A novel basal lamina matrix of the stratified epithelium of the ovarian follicle. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[61]  J. Risteli,et al.  Immunohistochemical study of type I collagen and type I pN‐collagen in benign and malignant ovarian neoplasms , 1995, Cancer.

[62]  U. Puistola,et al.  Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. , 1993, Cancer research.

[63]  J. Risteli,et al.  Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study , 1993, Cancer.

[64]  T. Kaku,et al.  Histological classification of ovarian cancer , 2003, Medical Electron Microscopy.

[65]  M. Deavers,et al.  The expression of decorin in human ovarian tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  J. Risteli,et al.  Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer. , 2001, Gynecologic oncology.

[67]  W. Knudson,et al.  Hyaluronan‐binding proteins in development, tissue homeostasis, and disease , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  E. Ruoslahti,et al.  Hyaluronate binding properties of versican. , 1992, The Journal of biological chemistry.

[69]  R. Timpl,et al.  Biglycan and Decorin Bind Close to the N-terminal Region of the Collagen VI Triple Helix* , 2001, The Journal of Biological Chemistry.

[70]  Y. Kawarada,et al.  Tenascin is a stromal marker for epithelial malignancy in the mammary gland. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[71]  G. Jayson,et al.  Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer , 2004, Clinical Cancer Research.

[72]  L. Bourguignon,et al.  CD44 Interaction with c-Src Kinase Promotes Cortactin-mediated Cytoskeleton Function and Hyaluronic Acid-dependent Ovarian Tumor Cell Migration* , 2001, The Journal of Biological Chemistry.

[73]  A. Rapraeger,et al.  Syndecans in tumor cell adhesion and signaling , 2004, Reproductive biology and endocrinology : RB&E.

[74]  M. Aziz,et al.  Clinical Evaluation of Serum Aminoterminal Propeptide of Type III Procollagen as Tumor Marker in Gynecologic Malignancies , 1993, Tumori.

[75]  P. Schwartz,et al.  Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival. , 2002, Gynecologic oncology.

[76]  P. Clement,et al.  Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament: Atlas of Tumor Pathology , 1999 .

[77]  R. Iozzo.  Matrix proteoglycans: from molecular design to cellular function. , 1998, Annual review of biochemistry.

[78]  D. Horsfall,et al.  Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer , 2004, Clinical Cancer Research.

[79]  Donald R Schwartz,et al.  Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. , 2003, Cancer cell.

[80]  S. Cannistra,et al.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. , 1997, Cancer research.

[81]  A. Freedman,et al.  Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  J. Filmus,et al.  Glypicans in growth control and cancer. , 2001, Glycobiology.

[83]  K. Münstedt,et al.  Association between fibronectin expression and prognosis in ovarian carcinoma. , 2003, Anticancer research.

[84]  K. Kimata,et al.  Hyaluronan synthase expression in ovarian cancer. , 2004, Oncology reports.

[85]  T. Kiviluoto,et al.  Laminin alpha1-chain shows a restricted distribution in epithelial basement membranes of fetal and adult human tissues. , 2000, Experimental cell research.

[86]  A. D. de Agostini,et al.  Anticoagulant heparan sulfate proteoglycans expression in the rat ovary peaks in preovulatory granulosa cells. , 2001, Glycobiology.

[87]  J. Risteli,et al.  Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo , 1999, British Journal of Cancer.

[88]  R. Rodgers,et al.  Development of the ovarian follicular epithelium , 1999, Molecular and Cellular Endocrinology.

[89]  P. Delmas,et al.  Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain , 1999, Journal of cellular biochemistry.

[90]  S. Ochsner,et al.  Processing and Localization of ADAMTS-1 and Proteolytic Cleavage of Versican during Cumulus Matrix Expansion and Ovulation* , 2003, Journal of Biological Chemistry.

[91]  R. Iozzo,et al.  An Anti-oncogenic Role for Decorin , 2000, The Journal of Biological Chemistry.

[92]  M J Bissell,et al.  Tissue architecture: the ultimate regulator of epithelial function? , 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[93]  R. Iozzo,et al.  Decorin prevents metastatic spreading of breast cancer , 2005, Oncogene.

[94]  H. Saito,et al.  Syndecan-4 expression is associated with follicular atresia in mouse ovary , 1999, Histochemistry and Cell Biology.

[95]  A. Friedl,et al.  Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis , 2006, Oncogene.

[96]  D. Russell,et al.  Extracellular matrix of the developing ovarian follicle. , 2003, Reproduction.

[97]  E. Vuorio,et al.  Cyclic expression of mRNA transcripts for connective tissue components in the mouse ovary. , 1999, Molecular human reproduction.

[98]  L. Bourguignon,et al.  Hyaluronan-CD44 Interaction with IQGAP1 Promotes Cdc42 and ERK Signaling, Leading to Actin Binding, Elk-1/Estrogen Receptor Transcriptional Activation, and Ovarian Cancer Progression* , 2005, Journal of Biological Chemistry.

[99]  C. Christiansen,et al.  Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.

[100]  G. Jayson,et al.  Heparan sulfate proteoglycans and cancer , 2001, British Journal of Cancer.

[101]  G. Keszler,et al.  Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. , 2005, Anticancer research.

[102]  Markku Santala,et al.  Type I and Type III Collagen Metabolites as Predictors of Clinical Outcome in Epithelial Ovarian Cancer , 1999 .

[103]  J. Risteli,et al.  Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[104]  P. Kruk,et al.  Ovarian surface epithelium: autonomous production of connective tissue-type extracellular matrix. , 1991, Biology of reproduction.

[105]  R. Einspanier,et al.  Expression of Hyaluronan Synthases and Corresponding Hyaluronan Receptors Is Differentially Regulated During Oocyte Maturation in Cattle1 , 2003, Biology of reproduction.

[106]  R. Iozzo.  Perlecan: a gem of a proteoglycan. , 1994, Matrix biology : journal of the International Society for Matrix Biology.

[107]  Y. Sado,et al.  Distribution of the α1 to α6 Chains of Type IV Collagen in Bovine Follicles , 1998 .

[108]  A. Godwin,et al.  Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis , 2002, Cancer.

[109]  T. Pihlajaniemi,et al.  Differential Expression of Laminin Isoforms in Ovarian Epithelial Carcinomas Suggesting Different Origin and Providing Tools for Differential Diagnosis , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[110]  R. Chiquet‐Ehrismann.  Tenascin and other adhesion-modulating proteins in cancer. , 1993, Seminars in cancer biology.

[111]  R. Timpl,et al.  Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. , 1993, Experimental cell research.

[112]  P. Marynen,et al.  Glypican-6, a New Member of the Glypican Family of Cell Surface Heparan Sulfate Proteoglycans* , 1999, The Journal of Biological Chemistry.

[113]  F. Stenbäck.  Collagen type III in ovarian tumors. Histological, immunohistochemical and ultrastructural findings. , 1989, European journal of obstetrics, gynecology, and reproductive biology.

[114]  A. Skubitz,et al.  CD44 and β1 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells , 1999 .

[115]  B. Werness,et al.  Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. , 2001 .

[116]  J. Schittny,et al.  Molecular architecture of basement membranes , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[117]  G. Turner,et al.  Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis , 1996, Clinical & Experimental Metastasis.

[118]  J. Risteli,et al.  Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125. , 2000, Anticancer research.

[119]  R. Kokenyesi.  Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix , 2001, Journal of cellular biochemistry.

[120]  P. Pujol,et al.  Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. , 1998, The American journal of pathology.

[121]  R. Timpl,et al.  Supramolecular assembly of basement membranes , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[122]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[123]  M. Schmitt,et al.  Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. , 1988, Cancer research.

[124]  A. Charchanti,et al.  Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. , 2004, Journal of experimental & clinical cancer research : CR.

[125]  J. Risteli,et al.  Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer. , 2003, Gynecologic oncology.

[126]  F. Stenbäck,et al.  Basement membrane structures in tumors of the ovary. , 1985, European journal of obstetrics, gynecology, and reproductive biology.

[127]  M. Paulsson,et al.  Basement membrane proteins: structure, assembly, and cellular interactions. , 1992, Critical reviews in biochemistry and molecular biology.